Short-Term Relapse Quantitation as a Fully Surrogate Endpoint for Long-Term Sustained Progression of Disability in RRMS Patients Treated with Natalizumab

Time to sustained worsening in the expanded disability status scale as the standard for evaluating the accumulation of disability has been used as a measure of clinical efficacy in many relapsing-remitting multiple sclerosis (RRMS) clinical trials. However, this measurement usually requires a large...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Y. C., Sandrock, A., Richert, J. R., Meyerson, L., Miao, X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253472/
https://www.ncbi.nlm.nih.gov/pubmed/22242202
http://dx.doi.org/10.1155/2011/195831

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253472/
https://www.ncbi.nlm.nih.gov/pubmed/22242202
http://dx.doi.org/10.1155/2011/195831

Ejemplares similares